Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10905872 | 0.89 | CA2 (0.49) | ALDH1A1CA2CYP2D6 | |
| SCHEMBL46416 | 0.85 | ALDH1A1 (0.56) | ALDH1A1CA2 | |
| SCHEMBL9778093 | 0.85 | ALDH1A1 (0.56) | ALDH1A1CA2 | |
| SCHEMBL9580528 | 0.85 | ALDH1A1 (0.56) | ALDH1A1CA2 | |
| SCHEMBL11932963 | 0.85 | ALDH1A1 (0.41) | ALDH1A1CA2 | |
| SCHEMBL14317553 | 0.84 | CA2 (0.45) | ALDH1A1CA2 | |
| SCHEMBL11939691 | 0.83 | CA2 (0.44) | ALDH1A1CA2 | |
| SCHEMBL29342844 | 0.82 | CA2 (0.37) | ALDH1A1CA2 | |
| SCHEMBL12921172 | 0.82 | CA2 (0.43) | ALDH1A1CA2 | |
| SCHEMBL13326873 | 0.81 | CA2 (0.45) | ALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151890-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-2939999-B1 | HIGH-PURITY MONOALKENYL-CONTAINING GLYCERIN DERIVATIVE, AND METHOD FOR PRODUCING SAME | DOW CORNING TORAY CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| EP-2720999-B1 | NOVEL LIPIDOMIMETIC COMPOUNDS AND USES THEREOF | KONINKLIJKE PHILIPS NV (NL) | 2017-08-23 | — | — | EP | disclosed |
| US-9663432-B2 | High-purity monoalkenyl-containing glycerin derivative and method of manufacturing same | DOW CORNING TORAY CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| US-9663432-B2 | High-purity monoalkenyl-containing glycerin derivative and method of manufacturing same | DOW CORNING TORAY CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| US-20160031781-A1 | AGENT FOR IMPROVING TISSUE PENETRATION | GENZYME CORPORATION (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031781-A1 | AGENT FOR IMPROVING TISSUE PENETRATION | GENZYME CORPORATION (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2939999-A1 | HIGH-PURITY MONOALKENYL-CONTAINING GLYCERIN DERIVATIVE, AND METHOD FOR PRODUCING SAME | Dow Corning Toray Co., Ltd. (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-9061062-B2 | Lipidomimetic compounds and uses thereof | KONINKLIJKE PHILIPS N.V. (NL) | 2015-06-23 | — | — | US | disclosed |
| US-9061062-B2 | Lipidomimetic compounds and uses thereof | KONINKLIJKE PHILIPS N.V. (NL) | 2015-06-23 | — | — | US | disclosed |
| US-20120064147-A1 | AGENT FOR IMPROVING TISSUE PENETRATION | GENZYME CORPORATION (US) | 2012-03-15 | — | — | US | disclosed |
| US-8076520-B2 | Phosphatidyl oligoglycerols | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20100280282-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2010-11-04 | — | — | US | disclosed |
| US-7709464-B2 | Phosphatidyl oligoglycerols | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20090312440-A1 | AGENT FOR IMPROVING TISSUE PENETRATION | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSHAFTEN E.V. (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312440-A1 | AGENT FOR IMPROVING TISSUE PENETRATION | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSHAFTEN E.V. (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090035358-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2009-02-05 | — | — | US | disclosed |
| US-7351428-B2 | Phosphatidyl oligoglycerols | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2008-04-01 | — | — | US | disclosed |
| US-20080003277-A1 | Agent for improving tissue penetration | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSHAFTEN E.V. (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20080003277-A1 | Agent for improving tissue penetration | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSHAFTEN E.V. (DE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080003277-A1 | Agent for improving tissue penetration | PGF, MMP8, MMP1 | ALDH1A1 1823/4885CA2 1449/4885CA1 1662/4885 |
| US-20100280282-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | PHOSPHO1, SGMS2, LIPG | ALDH1A1 3095/4885CA2 4175/4885CA1 4665/4885 |
| US-20090312440-A1 | AGENT FOR IMPROVING TISSUE PENETRATION | PGF, MMP8, MMP1 | ALDH1A1 1823/4885CA2 1449/4885CA1 1662/4885 |
| US-20090035358-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | PHOSPHO1, SGMS2, LIPG | ALDH1A1 3095/4885CA2 4175/4885CA1 4665/4885 |
| US-20160031781-A1 | AGENT FOR IMPROVING TISSUE PENETRATION | PGF, MMP8, MMP1 | ALDH1A1 1823/4885CA2 1449/4885CA1 1662/4885 |
| US-20120064147-A1 | AGENT FOR IMPROVING TISSUE PENETRATION | PGF, MMP8, MMP1 | ALDH1A1 1823/4885CA2 1449/4885CA1 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.